These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30275197)

  • 1. Proteomic Identification of FLT3 and PCBP3 as Potential Prognostic Biomarkers for Pancreatic Cancer.
    Ger M; Kaupinis A; Petrulionis M; Kurlinkus B; Cicenas J; Sileikis A; Valius M; Strupas K
    Anticancer Res; 2018 Oct; 38(10):5759-5765. PubMed ID: 30275197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival.
    Holm M; Saraswat M; Joenväärä S; Seppänen H; Renkonen R; Haglund C
    Tumour Biol; 2020 Jun; 42(6):1010428320936410. PubMed ID: 32586207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
    Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
    Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
    Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
    Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of UGP2 and CFL1 expression levels in benign and malignant pancreatic lesions and their clinicopathological significance.
    Wang L; Xiong L; Wu Z; Miao X; Liu Z; Li D; Zou Q; Yang Z
    World J Surg Oncol; 2018 Jan; 16(1):11. PubMed ID: 29347944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
    Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
    Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SWATH-MS based proteomic profiling of pancreatic ductal adenocarcinoma tumours reveals the interplay between the extracellular matrix and related intracellular pathways.
    Nweke EE; Naicker P; Aron S; Stoychev S; Devar J; Tabb DL; Omoshoro-Jones J; Smith M; Candy G
    PLoS One; 2020; 15(10):e0240453. PubMed ID: 33048956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma.
    Pozios I; Knösel T; Zhao Y; Assmann G; Pozios I; Müller MH; Bruns CJ; Kreis ME; Seeliger H
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1887-1897. PubMed ID: 30046904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor 2 and Toll-like receptor 4 predict favorable prognosis in local pancreatic cancer.
    Lanki MA; Seppänen HE; Mustonen HK; Böckelman C; Juuti AT; Hagström JK; Haglund CH
    Tumour Biol; 2018 Sep; 40(9):1010428318801188. PubMed ID: 30246618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
    Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
    Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
    Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
    Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets.
    Le Large TY; Mantini G; Meijer LL; Pham TV; Funel N; van Grieken NC; Kok B; Knol J; van Laarhoven HW; Piersma SR; Jimenez CR; Kazemier G; Giovannetti E; Bijlsma MF
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32634123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients.
    Tian M; Cui YZ; Song GH; Zong MJ; Zhou XY; Chen Y; Han JX
    BMC Cancer; 2008 Aug; 8():241. PubMed ID: 18706098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gli1 expression in pancreatic ductal adenocarcinoma and its clinical significance.
    Abula Y; Yi C; Wang XY; Wang M; Qin RY; Guo YQ; Lin H; Li HJ
    Genet Mol Res; 2015 Oct; 14(4):12323-9. PubMed ID: 26505381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
    Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
    Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
    Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Clinical Patients with Pancreatic Cancer.
    Suzuki K; Watanabe A; Araki K; Yokobori T; Harimoto N; Gantumur D; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Kubo N; Gombodorj N; Nishiyama M; Hosouchi Y; Kuwano H; Shirabe K
    Anticancer Res; 2018 Feb; 38(2):939-944. PubMed ID: 29374725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.
    Martinez-Useros J; Georgiev-Hristov T; Fernández-Aceñero MJ; Borrero-Palacios A; Indacochea A; Guerrero S; Li W; Cebrián A; Gómez Del Pulgar T; Puime-Otin A; Del Puerto-Nevado L; Rodríguez-Remírez M; Pérez N; Celdrán A; Gebauer F; Garcia-Foncillas J
    PLoS One; 2017; 12(8):e0182044. PubMed ID: 28763470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma.
    Kitamura F; Miyata T; Uemura N; Uchihara T; Imai K; Hayashi H; Yamashita YI; Matsusaki K; Ishimoto T; Baba H
    Anticancer Res; 2021 Jun; 41(6):2895-2900. PubMed ID: 34083280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma.
    Iuga C; Seicean A; Iancu C; Buiga R; Sappa PK; Völker U; Hammer E
    Proteomics; 2014 Apr; 14(7-8):945-55. PubMed ID: 24459066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.